"Even though it has risen quite a lot the share price is low by historical standards. If the company can increase (well, at this point, re-create) a profit from the huge annual revenue base the company will do very well."
@Dazaau,
Your last sentence is the nub of the issue.
You only need to convert a thin slither of all that Revenue into Profit and you have a lot of Profit in the context of the $200m market value of the company.
This company happily generated $30m in EBIT at one stage of its life (and on an asset base roughly half of what it is today):
Even if management didn't get EBIT all the way back to the glory days of $30m-plus, but to $23m pa to $25m pa, that would leave the stock trading on a mere 8.0x to 9x EV/EBIT, which are not overly demanding multiples despite the doubling of the share price over the past few months, to a two-year high.
.
- Forums
- ASX - By Stock
- TRS
- Ann: Change in substantial holding
Ann: Change in substantial holding, page-10
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
New gold and silver soil anomalies uncovered at Black Range, strengthening exploration potential
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add TRS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.16 |
Change
0.000(0.00%) |
Mkt cap ! $117.8M |
Open | High | Low | Value | Volume |
$3.17 | $3.17 | $3.16 | $48.59K | 15.36K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5761 | $3.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.19 | 334 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5761 | 3.160 |
4 | 3131 | 3.150 |
2 | 20312 | 3.140 |
1 | 958 | 3.130 |
3 | 13903 | 3.120 |
Price($) | Vol. | No. |
---|---|---|
3.190 | 334 | 4 |
3.200 | 895 | 1 |
3.210 | 2574 | 1 |
3.220 | 159 | 1 |
3.230 | 1640 | 1 |
Last trade - 14.18pm 10/10/2024 (20 minute delay) ? |
Featured News
TRS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online